Lv2
180 积分 2022-09-14 加入
Quad‐class exposed/refractory myeloma is associated with short survival
20天前
已完结
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax
21天前
已完结
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
21天前
已完结
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
21天前
已完结
A review of treatment options employed in relapsed/refractory AML
22天前
已完结
BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia
1个月前
已完结
Advances in Treatment of Waldenström Macroglobulinemia
1个月前
已完结
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
1个月前
已完结
Multiple myeloma
1个月前
已完结
A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study
2个月前
已完结
皖公网安备34019202002308
